Envafolimab

Baculovirus-insect cell expression uses recombinant baculovirus to deliver a target gene into insect cells, where late or very-late viral transcription drives recombinant protein production; the method was classically demonstrated by expression of human β-interferon in baculovirus-infected insect cells. The readout is target protein accumulation, assessed by activity, fluorescence if a fluorescent reporter is used, SDS-PAGE, Western blot, or purified protein yield. The system can express soluble, secreted, membrane-associated, and multiprotein targets, but expression outcome depends on the construct, baculovirus vector, insect cell line, multiplicity of infection, infection cell density, harvest time, and target-specific stability.

Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.

The purification of soluble recombinant proteins in Escherichia coli is achieved by fusing the target protein with a solubility-enhancing affinity tag (e. g. , His-tag, GST, MBP, Fh8, CSQ-tag, or thioredoxin) to improve expression yield, prevent aggregation, and enable efficient purification via affinity chromatography. The fusion protein is expressed under inducible promoters (e. g. , IPTG-induced T7 promoter), lysed from bacterial cells, and purified using resin-based affinity chromatography (e. g. , Ni-NTA for His-tag, amylose resin for MBP, chitin resin for intein tags, or HIC for Fh8). Tags can be removed post-purification using site-specific proteases (e. g. , TEV, enterokinase) or through intracellular cleavage systems. Solubility screening using multiple fusion partners (e. g. , Expresso® system) allows optimization of expression conditions for difficult-to-express proteins.

Inclusion-body recovery uses insoluble recombinant protein aggregates from E. coli as a starting material; the workflow is cell disruption, inclusion-body isolation/washing, denaturant or mild solubilization, refolding into soluble protein, and final chromatographic purification. The readouts are soluble protein recovery, purity by SDS-PAGE/chromatography, structural recovery by methods such as circular dichroism when used, and biological activity when an assay is available.

Recombinant protein expression in Escherichia coli followed by purification of a His-tagged soluble protein by immobilized metal affinity chromatography (IMAC), with optional MBP fusion and TEV tag removal when the construct includes these elements. The biological readout is production of the encoded target protein, detected as an inducible band at the expected molecular mass by SDS-PAGE and quantified by total protein assay or chromatographic absorbance; the purification readout is enrichment of the target protein in elution fractions after selective binding of polyhistidine residues to immobilized Ni2+/metal-chelate resin and elution by imidazole-containing buffer. Expression is driven by an inducible bacterial expression system, commonly T7/lac-based, in which IPTG or lactose/auto-induction activates transcription and translation of the cloned gene; lower induction temperature, lower inducer concentration, induction timing, and solubility-enhancing fusion tags can influence the frac

Mammalian transient protein expression introduces plasmid DNA into HEK293 or CHO cells for short-term recombinant protein production, allowing secreted, glycosylated, Fc-tagged, His-tagged, or membrane proteins to be produced without stable clone generation.